Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1463-70. Epub 2008 Jul 4.
Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease.
Department of Pharmacology, School of Medicine, University of Western Sydney, Australia.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that destroys patient memory and cognition, communication ability with the social environment and the ability to carry out daily activities. Despite extensive research into the pathogenesis of AD, a neuroprotective treatment – particularly for the early stages of disease – remains unavailable for clinical use. In this review, we advance the suggestion that lipoic acid (LA) may fulfil this therapeutic need.
A naturally occurring cofactor for the mitochondrial enzymes pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, LA has been shown to have a variety of properties which can interfere with the pathogenesis or progression of AD. For example, LA increases acetylcholine (ACh) production by activation of choline acetyltransferase and increases glucose uptake, thus supplying more acetyl-CoA for the production of ACh. LA chelates redox-active transition metals, thus inhibiting the formation of hydroxyl radicals and also scavenges reactive oxygen species (ROS), thereby increasing the levels of reduced glutathione. In addition, LA down-regulates the expression of redox-sensitive pro-inflammatory proteins including TNF and inducible nitric oxide synthase. Furthermore, LA can scavenge lipid peroxidation products such as hydroxynonenal and acrolein.
In human plasma, LA exists in an equilibrium of free and plasma protein bound form. Up to 150 muM, it is bound completely, most likely binding to high affinity fatty acid sites on human serum albumin, suggesting that one large dose rather than continuous low doses (as provided by “slow release” LA) will be beneficial for delivery of LA to the brain. Evidence for a clinical benefit for LA in dementia is yet limited. There are only two published studies, in which 600 mg LA was given daily to 43 patients with AD (receiving a standard treatment with choline-esterase inhibitors) in an open-label study over an observation period of up to 48 months. Whereas the improvement in patients with moderate dementia was not significant, the disease progressed extremely slowly (change in ADAScog: 1.2 points=year, MMSE: -0.6 points=year) in patients with mild dementia (ADAScog<15). Data from cell culture and animal models suggest that LA could be combined with nutraceuticals such as curcumin, (-)-epigallocatechin gallate (from green tea) and docosahexaenoic acid (from fish oil) to synergistically decrease oxidative stress, inflammation, Abeta levels and Abeta plaque load and thus provide a combined benefit in the treatment of AD.
SEE MORE SCIENCE BELOW
Alzheimer’s disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners.
Wollen KA. Altern Med Rev. 2010 Sep;15(3):223-44. Review.
Di Stefano A, Sozio P, Cerasa LS, Iannitelli A, Cataldi A, Zara S, Giorgioni G, Nasuti C.
Int J Immunopathol Pharmacol. 2010 Apr-Jun;23(2):589-99.
Sozio P, D’Aurizio E, Iannitelli A, Cataldi A, Zara S, Cantalamessa F, Nasuti C, Di Stefano A.
Arch Pharm (Weinheim). 2010 Mar;343(3):133-42.
Cho JY, Um HS, Kang EB, Cho IH, Kim CH, Cho JS, Hwang DY.
Int J Mol Med. 2010 Mar;25(3):337-46.
Bolognesi ML, Cavalli A, Bergamini C, Fato R, Lenaz G, Rosini M, Bartolini M, Andrisano V, Melchiorre C.
J Med Chem. 2009 Dec 10;52(23):7883-6.
Liu RT, LÃ¼ QJ.
Yao Xue Xue Bao. 2009 Mar;44(3):258-63. Review. Chinese.
Shenk JC, Liu J, Fischbach K, Xu K, Puchowicz M, Obrenovich ME, Gasimov E, Alvarez LM, Ames BN, Lamanna JC, Aliev G.
J Neurol Sci. 2009 Aug 15;283(1-2):199-206. Epub 2009 Apr 1.
Bolognesi ML, Rosini M, Andrisano V, Bartolini M, Minarini A, Tumiatti V, Melchiorre C.
Curr Pharm Des. 2009;15(6):601-13. Review.
Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance.
Suchy J, Chan A, Shea TB.
Nutr Res. 2009 Jan;29(1):70-4.
Siedlak SL, Casadesus G, Webber KM, Pappolla MA, Atwood CS, Smith MA, Perry G.
Free Radic Res. 2009 Feb;43(2):156-64.
Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, Carlson DA, MÃ¼nch G.
Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1463-70. Epub 2008 Jul 4. Review.
Salinthone S, Yadav V, Bourdette DN, Carr DW.
Endocr Metab Immune Disord Drug Targets. 2008 Jun;8(2):132-42. Review.
Hager K, Kenklies M, McAfoose J, Engel J, MÃ¼nch G.
J Neural Transm Suppl. 2007;(72):189-93.
Moreira PI, Harris PL, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G.
J Alzheimers Dis. 2007 Sep;12(2):195-206. Review.
Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M, Nunomura A, Szweda LI, Aliev G, Smith MA, Zhu X, Perry G.
J Neuropathol Exp Neurol. 2007 Jun;66(6):525-32. Erratum in: J Neuropathol Exp Neurol. 2007 Jul;66(7):674.
Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer’s disease.
Abdul HM, Butterfield DA.
Free Radic Biol Med. 2007 Feb 1;42(3):371-84. Epub 2006 Nov 10.
Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, Engel J, MÃ¼nch G.
Pharmacol Ther. 2007 Jan;113(1):154-64. Epub 2006 Sep 20. Review.
McIntyre RS, Soczynska JK, Lewis GF, MacQueen GM, Konarski JZ, Kennedy SH.
Expert Opin Pharmacother. 2006 Jul;7(10):1305-21.
Cui X, Zuo P, Zhang Q, Li X, Hu Y, Long J, Packer L, Liu J.
J Neurosci Res. 2006 Aug 15;84(3):647-54.
Quinn JF, Bussiere JR, Hammond RS, Montine TJ, Henson E, Jones RE, Stackman RW Jr.
Neurobiol Aging. 2007 Feb;28(2):213-25. Epub 2006 Jan 31.